These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 6430312)
21. Comparative studies with Fluosol, Dextran, their mixture, or autologous blood in experimental hypovolemic shock. Madjidi A; Beisbarth H; Frey R Prog Clin Biol Res; 1983; 122():391-7. PubMed ID: 6192451 [TBL] [Abstract][Full Text] [Related]
22. High oxygen delivery and extraction by perfluorocarbon-primed extracorporeal membrane oxygenation do not prevent anaerobic metabolism in rabbits. Iwao Y; Tashiro M; Iijima T; Masuda J; Sankawa H J Pediatr Surg; 1998 Mar; 33(3):422-7. PubMed ID: 9537551 [TBL] [Abstract][Full Text] [Related]
23. The influence of oxygenation on the 19F spin-lattice relaxation rates of fluosol-DA. Reid RS; Koch CJ; Castro ME; Lunt JA; Treiber EO; Boisvert DJ; Allen PS Phys Med Biol; 1985 Jul; 30(7):677-86. PubMed ID: 4023055 [TBL] [Abstract][Full Text] [Related]
24. Initial Canadian experience with artificial blood (Fluosol-DA-20%) in severely anemic patients. Stefaniszyn HJ; Wynands JE; Salerno TA J Cardiovasc Surg (Torino); 1985; 26(4):337-42. PubMed ID: 4019576 [TBL] [Abstract][Full Text] [Related]
25. Transperitoneal oxygenation with fluorocarbons. Klein J; Faithfull NS; Salt PJ; Trouwborst A Anesth Analg; 1986 Jul; 65(7):734-8. PubMed ID: 3717613 [TBL] [Abstract][Full Text] [Related]
26. Changes of hemodynamics and O2 transport associated with the perfluorochemical blood substitute, Fluosol-DA. Nishimura N; Sugi T Crit Care Med; 1984 Jan; 12(1):36-8. PubMed ID: 6690204 [TBL] [Abstract][Full Text] [Related]
27. Increased radiosensitivity of tumors by perfluorochemicals and carbogen. Song CW; Zhang WL; Pence DM; Lee I; Levitt SH Int J Radiat Oncol Biol Phys; 1985 Oct; 11(10):1833-6. PubMed ID: 3930442 [TBL] [Abstract][Full Text] [Related]
29. Effects of haemodilution with fluorocarbons or dextran on oxygen tensions in the acutely ischaemic myocardium. Faithfull NS; Erdmann W; Fennema M; Kok A Br J Anaesth; 1986 Sep; 58(9):1031-40. PubMed ID: 2428389 [TBL] [Abstract][Full Text] [Related]
31. The effect of fluosol-DA and oxygenation status on the activity of cyclophosphamide in vivo. Teicher BA; Herman TS; Holden SA; Cathcart KN Cancer Chemother Pharmacol; 1988; 21(4):286-91. PubMed ID: 3131033 [TBL] [Abstract][Full Text] [Related]
32. Inadequate subendocardial oxygen delivery during perfluorocarbon perfusion in a canine model of ischemia. Christensen CW; Reeves WC; Lassar TA; Schmidt DH Am Heart J; 1988 Jan; 115(1 Pt 1):30-7. PubMed ID: 3336983 [TBL] [Abstract][Full Text] [Related]
33. Increased infection mortality and decreased neutrophil migration due to a component of an artificial blood substitute. Lane TA; Lamkin GE Blood; 1986 Aug; 68(2):351-4. PubMed ID: 3524707 [TBL] [Abstract][Full Text] [Related]
34. [The place for using erythrocyte substitutes in hemodilution: fluosol-DA and polymerized pyridoxylated hemoglobin]. Vigneron C; Labrude P; Dellacherie E Ann Fr Anesth Reanim; 1986; 5(3):260-8. PubMed ID: 3535579 [TBL] [Abstract][Full Text] [Related]
35. Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Kerins DM Am J Med Sci; 1994 Mar; 307(3):218-21. PubMed ID: 8160713 [No Abstract] [Full Text] [Related]
36. Stability of perfluorocarbon blood substitutes determined by sedimentation field-flow fractionation. Yang FS; Caldwell KD; Giddings JC; Astle L Anal Biochem; 1984 May; 138(2):488-94. PubMed ID: 6742424 [TBL] [Abstract][Full Text] [Related]